Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.

Qian X, Durkin ME, Wang D, Tripathi BK, Olson L, Yang XY, Vass WC, Popescu NC, Lowy DR.

Cancer Res. 2012 Nov 15;72(22):5900-11. doi: 10.1158/0008-5472.CAN-12-2368. Epub 2012 Sep 25.

2.

Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.

Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI, Lowy DR.

Cancer Res. 2012 Sep 1;72(17):4405-16. doi: 10.1158/0008-5472.CAN-12-0777. Epub 2012 Jun 12.

3.

Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).

Li G, Du X, Vass WC, Papageorge AG, Lowy DR, Qian X.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17129-34. doi: 10.1073/pnas.1112122108. Epub 2011 Oct 3.

4.

E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases.

Asnaghi L, Vass WC, Quadri R, Day PM, Qian X, Braverman R, Papageorge AG, Lowy DR.

Oncogene. 2010 May 13;29(19):2760-71. doi: 10.1038/onc.2010.39. Epub 2010 Mar 15.

5.

The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis.

Qian X, Li G, Vass WC, Papageorge A, Walker RC, Asnaghi L, Steinbach PJ, Tosato G, Hunter K, Lowy DR.

Cancer Cell. 2009 Sep 8;16(3):246-58. doi: 10.1016/j.ccr.2009.07.031.

6.

Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility.

Zhang K, Kagan D, DuBois W, Robinson R, Bliskovsky V, Vass WC, Zhang S, Mock BA.

Blood. 2009 Oct 1;114(14):2952-60. doi: 10.1182/blood-2009-01-198812. Epub 2009 Aug 4.

7.

ASAP3 is a focal adhesion-associated Arf GAP that functions in cell migration and invasion.

Ha VL, Bharti S, Inoue H, Vass WC, Campa F, Nie Z, de Gramont A, Ward Y, Randazzo PA.

J Biol Chem. 2008 May 30;283(22):14915-26. doi: 10.1074/jbc.M709717200. Epub 2008 Apr 8.

8.

Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.

Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG, Lowy DR.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):9012-7. Epub 2007 May 15.

9.

Specific regulation of the adaptor protein complex AP-3 by the Arf GAP AGAP1.

Nie Z, Boehm M, Boja ES, Vass WC, Bonifacino JS, Fales HM, Randazzo PA.

Dev Cell. 2003 Sep;5(3):513-21.

11.

Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model.

Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE.

Cancer Res. 2002 Aug 1;62(15):4507-13.

12.

The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination.

Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wienecke R, DeClue JE.

Oncogene. 2000 Dec 14;19(54):6306-16.

13.

NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.

Pastrana DV, Vass WC, Lowy DR, Schiller JT.

Virology. 2001 Jan 5;279(1):361-9.

14.

Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.

Zhang SL, DuBois W, Ramsay ES, Bliskovski V, Morse HC 3rd, Taddesse-Heath L, Vass WC, DePinho RA, Mock BA.

Mol Cell Biol. 2001 Jan;21(1):310-8.

15.

Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models.

DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W, Vass WC, Viskochil D, Ratner N.

J Clin Invest. 2000 May;105(9):1233-41.

16.

The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties.

Qian X, Esteban L, Vass WC, Upadhyaya C, Papageorge AG, Yienger K, Ward JM, Lowy DR, Santos E.

EMBO J. 2000 Feb 15;19(4):642-54.

17.

Ras-specific exchange factor GRF: oligomerization through its Dbl homology domain and calcium-dependent activation of Raf.

Anborgh PH, Qian X, Papageorge AG, Vass WC, DeClue JE, Lowy DR.

Mol Cell Biol. 1999 Jul;19(7):4611-22.

18.

N terminus of Sos1 Ras exchange factor: critical roles for the Dbl and pleckstrin homology domains.

Qian X, Vass WC, Papageorge AG, Anborgh PH, Lowy DR.

Mol Cell Biol. 1998 Feb;18(2):771-8.

19.
20.

Co-localization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus.

Wienecke R, Maize JC Jr, Shoarinejad F, Vass WC, Reed J, Bonifacino JS, Resau JH, de Gunzburg J, Yeung RS, DeClue JE.

Oncogene. 1996 Sep 5;13(5):913-23.

PMID:
8806680
21.
22.

Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function.

Johnson MR, DeClue JE, Felzmann S, Vass WC, Xu G, White R, Lowy DR.

Mol Cell Biol. 1994 Jan;14(1):641-5.

23.

Regulated and constitutive activity by CDC25Mm (GRF), a Ras-specific exchange factor.

Cen H, Papageorge AG, Vass WC, Zhang KE, Lowy DR.

Mol Cell Biol. 1993 Dec;13(12):7718-24.

24.

Functional role of GTPase-activating protein in cell transformation by pp60v-src.

DeClue JE, Vass WC, Johnson MR, Stacey DW, Lowy DR.

Mol Cell Biol. 1993 Nov;13(11):6799-809.

26.

Cell transformation by ras and regulation of its protein product.

Lowy DR, Johnson MR, DeClue JE, Cen H, Zhang K, Papageorge AG, Vass WC, Willumsen BM, Valentine MB, Look AT.

Ciba Found Symp. 1993;176:67-80; discussion 80-4. Review.

PMID:
8299427
28.

Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis.

DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR.

Cell. 1992 Apr 17;69(2):265-73.

PMID:
1568246
29.

Heterogeneous amino acids in Ras and Rap1A specifying sensitivity to GAP proteins.

Zhang K, Papageorge AG, Martin P, Vass WC, Olah Z, Polakis PG, McCormick F, Lowy DR.

Science. 1991 Dec 13;254(5038):1630-4.

PMID:
1749934
30.

The bovine papillomavirus E5 oncogene can cooperate with ras: identification of p21 amino acids critical for transformation by c-rasH but not v-rasH.

Willumsen BM, Vass WC, Velu TJ, Papageorge AG, Schiller JT, Lowy DR.

Mol Cell Biol. 1991 Dec;11(12):6026-33.

31.
32.
33.

The biological activity of the human epidermal growth factor receptor is positively regulated by its C-terminal tyrosines.

Helin K, Velu T, Martin P, Vass WC, Allevato G, Lowy DR, Beguinot L.

Oncogene. 1991 May;6(5):825-32.

PMID:
1646987
34.

Tumorigenic transformation of NIH 3T3 cells by the autocrine synthesis of transforming growth factor alpha.

Ju WD, Velu TJ, Vass WC, Papageorge AG, Lowy DR.

New Biol. 1991 Apr;3(4):380-8.

PMID:
2065023
35.

Inhibition of cell growth by lovastatin is independent of ras function.

DeClue JE, Vass WC, Papageorge AG, Lowy DR, Willumsen BM.

Cancer Res. 1991 Jan 15;51(2):712-7.

36.
37.

Suppression of c-ras transformation by GTPase-activating protein.

Zhang K, DeClue JE, Vass WC, Papageorge AG, McCormick F, Lowy DR.

Nature. 1990 Aug 23;346(6286):754-6.

PMID:
2201922
38.

Identification of small clusters of divergent amino acids that mediate the opposing effects of ras and Krev-1.

Zhang K, Noda M, Vass WC, Papageorge AG, Lowy DR.

Science. 1990 Jul 13;249(4965):162-5.

PMID:
2115210
39.

Selective potentiation of c-fps/fes transforming activity by a phosphatase inhibitor.

Feldman RA, Lowy DR, Vass WC.

Oncogene Res. 1990;5(3):187-97.

PMID:
2157188
40.
41.

The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors.

Martin P, Vass WC, Schiller JT, Lowy DR, Velu TJ.

Cell. 1989 Oct 6;59(1):21-32.

PMID:
2551505
43.
44.

Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay.

Velu TJ, Beguinot L, Vass WC, Zhang K, Pastan I, Lowy DR.

J Cell Biochem. 1989 Feb;39(2):153-66.

PMID:
2565908
45.

The role of v-mos in transformation, oncogenicity, and metastatic potential of mink lung cells.

Gao CL, Wang LC, Vass WC, Seth A, Chang KS.

Oncogene. 1988 Sep;3(3):267-73.

PMID:
2849740
46.

p21-ras effector domain mutants constructed by "cassette" mutagenesis.

Stone JC, Vass WC, Willumsen BM, Lowy DR.

Mol Cell Biol. 1988 Aug;8(8):3565-9.

47.

Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene.

Velu TJ, Beguinot L, Vass WC, Willingham MC, Merlino GT, Pastan I, Lowy DR.

Science. 1987 Dec 4;238(4832):1408-10.

PMID:
3500513
48.
49.

Mutational analysis of a ras catalytic domain.

Willumsen BM, Papageorge AG, Kung HF, Bekesi E, Robins T, Johnsen M, Vass WC, Lowy DR.

Mol Cell Biol. 1986 Jul;6(7):2646-54.

50.

A transforming ras gene can provide an essential function ordinarily supplied by an endogenous ras gene.

Papageorge AG, Willumsen BM, Johnsen M, Kung HF, Stacey DW, Vass WC, Lowy DR.

Mol Cell Biol. 1986 May;6(5):1843-6.

Supplemental Content

Support Center